1. Executive Summary
1.1.Regional Market Share
1.2. Business Trends
1.3.Vaccines Market: COVID-19 Outbreak
1.4.Regional Trends
1.5. Segmentation Snapshot
2. Research Methodology
2.1. Research Objective
2.2.Research Approach
2.3.Data Sourcing and Methodology
2.4. Primary Research
2.5. Secondary Research
2.5.1. Paid Sources
2.5.2.Public Sources
2.6.Market Size Estimation and Data Triangulation
3. Market Characteristics
3.1. Market Definition
3.2.Vaccines Market: COVID-19 Impact
3.3.Key Segmentations
3.4. Key Developments
3.5. Allied Industry Data
4. Vaccines Market – Industry Insights
4.1.Industry Segmentation
4.2. COVID-19 overview of world economy
4.3. Industry Ecosystem Channel Analysis
4.4. Innovation & Sustainability
5. Macroeconomic Indicators
6. Recent Developments
7.Market Dynamics
7.1. Introduction
7.2.Growth Drivers
7.3.Market Opportunities
7.4. Market Restraints
7.5.Market Trends
8. Risk Analysis
9. Market Analysis
9.1. Porter's Five Forces
9.2.PEST Analysis
9.2.1. Political
9.2.2.Economic
9.2.3.Social
9.2.4.Technological
10. Vaccines Market
10.1.Overview
10.2. Historical Analysis (2019-2022)
10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
11.Vaccines Market Size & Forecast 2024A-2034F
11.1.Overview
11.2. Key Findings
11.3. Market Segmentation
11.3.1. By Technology
11.3.1.1. Conjugate
11.3.1.1.1. By Value (USD Million) 2024-2034F
11.3.1.1.2.Market Share (%) 2024-2034F
11.3.1.1.3.Y-o-Y Growth (%) 2024-2034F
11.3.1.2.Recombinant
11.3.1.2.1.By Value (USD Million) 2024-2034F
11.3.1.2.2. Market Share (%) 2024-2034F
11.3.1.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.1.3.Live Attenuated
11.3.1.3.1.By Value (USD Million) 2024-2034F
11.3.1.3.2. Market Share (%) 2024-2034F
11.3.1.3.3. Y-o-Y Growth (%) 2024-2034F
11.3.1.4.Toxoid
11.3.1.4.1.By Value (USD Million) 2024-2034F
11.3.1.4.2. Market Share (%) 2024-2034F
11.3.1.4.3. Y-o-Y Growth (%) 2024-2034F
11.3.1.5.Viral Vector
11.3.1.5.1.By Value (USD Million) 2024-2034F
11.3.1.5.2. Market Share (%) 2024-2034F
11.3.1.5.3. Y-o-Y Growth (%) 2024-2034F
11.3.1.6.mRNA
11.3.1.6.1.By Value (USD Million) 2024-2034F
11.3.1.6.2. Market Share (%) 2024-2034F
11.3.1.6.3. Y-o-Y Growth (%) 2024-2034F
11.3.2. By Type
11.3.2.1.Monovalent
11.3.2.1.1.By Value (USD Million) 2024-2034F
11.3.2.1.2. Market Share (%) 2024-2034F
11.3.2.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.2. Multivalent
11.3.2.2.1. By Value (USD Million) 2024-2034F
11.3.2.2.2.Market Share (%) 2024-2034F
11.3.2.2.3.Y-o-Y Growth (%) 2024-2034F
11.3.3. By Disease
11.3.3.1.Pneumococcal
11.3.3.1.1.By Value (USD Million) 2024-2034F
11.3.3.1.2. Market Share (%) 2024-2034F
11.3.3.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.2. Flu
11.3.3.2.1. By Value (USD Million) 2024-2034F
11.3.3.2.2.Market Share (%) 2024-2034F
11.3.3.2.3.Y-o-Y Growth (%) 2024-2034F
11.3.3.3. HPV
11.3.3.3.1. By Value (USD Million) 2024-2034F
11.3.3.3.2.Market Share (%) 2024-2034F
11.3.3.3.3.Y-o-Y Growth (%) 2024-2034F
11.3.3.4. Herpes Zoster
11.3.3.4.1. By Value (USD Million) 2024-2034F
11.3.3.4.2. Market Share (%) 2024-2034F
11.3.3.4.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.5. MMR
11.3.3.5.1. By Value (USD Million) 2024-2034F
11.3.3.5.2.Market Share (%) 2024-2034F
11.3.3.5.3.Y-o-Y Growth (%) 2024-2034F
11.3.3.6. Rotavirus
11.3.3.6.1. By Value (USD Million) 2024-2034F
11.3.3.6.2.Market Share (%) 2024-2034F
11.3.3.6.3.Y-o-Y Growth (%) 2024-2034F
11.3.3.7. RSV
11.3.3.7.1. By Value (USD Million) 2024-2034F
11.3.3.7.2.Market Share (%) 2024-2034F
11.3.3.7.3.Y-o-Y Growth (%) 2024-2034F
11.3.4. By Route of Administration
11.3.4.1.Parenteral
11.3.4.1.1.By Value (USD Million) 2024-2034F
11.3.4.1.2. Market Share (%) 2024-2034F
11.3.4.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.4.2. Oral
11.3.4.2.1. By Value (USD Million) 2024-2034F
11.3.4.2.2.Market Share (%) 2024-2034F
11.3.4.2.3. Y-o-Y Growth (%) 2024-2034F
12. North America Vaccines Market Size & Forecast 2024A-2034F
12.1. Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1. By Technology
12.3.2.By Type
12.3.3.By Disease
12.3.4.By Route of Administration
12.4. Country
12.4.1.United States
12.4.2. Canada
13. Europe Vaccines Market Size & Forecast 2024A-2034F
13.1. Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1. By Technology
13.3.2.By Type
13.3.3.By Disease
13.3.4.By Route of Administration
13.4. Country
13.4.1.Germany
13.4.2.United Kingdom
13.4.3.France
13.4.4. Italy
13.4.5.Spain
13.4.6.Russia
13.4.7.Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
14. Asia-Pacific Vaccines Market Size & Forecast 2024A-2034F
14.1.Overview
14.2. Key Findings
14.3. Market Segmentation
14.3.1. By Technology
14.3.2.By Type
14.3.3.By Disease
14.3.4. By Route of Administration
14.4. Country
14.4.1. India
14.4.2.China
14.4.3. South Korea
14.4.4. Japan
14.4.5. Rest of APAC
15. Middle East and Africa Vaccines Market Size & Forecast 2024A-2034F
15.1.Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1. By Technology
15.3.2.By Type
15.3.3.By Disease
15.3.4.By Route of Administration
15.4. Country
15.4.1.Israel
15.4.2. GCC
15.4.3. North Africa
15.4.4.South Africa
15.4.5. Rest of Middle East and Africa
16. Latin America Vaccines Market Size & Forecast 2024A-2034F
16.1. Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1. By Technology
16.3.2.By Type
16.3.3.By Disease
16.3.4.By Route of Administration
16.4. Country
16.4.1. Mexico
16.4.2. Brazil
16.4.3. Rest of Latin America
17. Competitive Landscape
17.1. Company market share, 2023
17.2.Key player overview
17.3. Key stakeholders
18. Company Profiles
18.1.Pfizer
18.1.1.Company Overview
18.1.2.Financial Overview
18.1.3.Key Product; Analysis
18.1.4.Company Assessment
18.1.4.1.Product Portfolio
18.1.4.2. Key Clients
18.1.4.3. Market Share
18.1.4.4. Recent News & Development (Last 3 Yrs.)
18.1.4.5. Executive Team
18.2.GlaxoSmithKline (GSK)
18.3.Merck & Co.
18.4.Sanofi Pasteur
18.5.Serum Institute of India
18.6.AstraZeneca
18.7.Novavax
18.8.Moderna
18.9.Johnson & Johnson
18.10.CSL Limited
18.11. Bharat Biotech
18.12.Sinovac Biotech
18.13.CanSino Biologics
18.14.Dynavax Technologies
18.15.Valneva
18.16.Other Prominent Players
19. Appendix
20.Consultant Recommendation
Select License Type
Our Clients
We have been working with some Fortune 500+ clients
.png){kind=icon}
